Komal Jhaveri, MD, Memorial Sloan Kettering Cancer Center and lead author of the EMBER-3 trial, as she discusses the significance of this approval, its impact on the treatment…
Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, reports on results from the East Asian subgroup of the Phase 3 EMBER‑3 trial, showing that in patients…
Charles Marmar, MD, chair and director of the Department of Psychiatry – PTSD Research Program at NYU Langone Health, shares details about the potential to leverage artificial intelligence…
Ed Kelly, PhD, Assistant Director of the Pharmaceutical Bioengineering Extension Program at the University of Washington School of Pharmacy, and co-researcher Jonathan Himmelfarb, MD, are leading a study…
The US Food and Drug Administration (FDA) has approved the immunotherapy avelumab in combination with the tyrosine kinase inhibitor axitinib for the first-line treatment of patients with advanced renal cell carcinoma (RCC). The…
According to the Associated Press’ search of a U.S. government database, six of the eight currently registered clinical trials studying deep brain stimulation (DBS) for addiction treatment are…
Researchers in Australia are developing new approaches to blocking inflammasomes, the multiprotein molecular complex that stimulates the body’s inflammatory immune response and drives the progression of Parkinson’s disease…
The enormously popular video game Fortnite gives rise to hours-long marathon playing sessions—and now there’s evidence that it creates health problems in young players as well. According to…
A new cancer treatment combines conventional chemotherapy drugs with a digital sensor in a single capsule. Developed by biotech company Proteus Digital Health, the “digital medicine solution” communicates…
Researchers may have cracked an important code in the influenza virus, one that may lead to the development of flu vaccines that remain potent for up to 10…
